Table 1 Baseline characteristics of bromocriptine treated patients and matched controls †
Variable | Bromocriptine (n = 3035) | Controls (n = 15,175) | p-value |
|---|---|---|---|
Age at onset (year) | 31.7 [27.8, 36.8] | 31.7 [27.7, 36.8] | - |
Comorbidities, n (%) | |||
Ischemic heart disease | 20 (0.7) | 64 (0.4) | 0.11 |
Acute myocardial infarction | 5 (0.2) | 20 (0.1) | 0.86 |
Atrial fibrillation | 8 (0.3) | 27 (0.2) | 0.45 |
Ischemic stroke | 15 (0.5) | 50 (0.3) | 0.22 |
Transient ischemic attack | 7 (0.2) | 19 (0.1) | 0.25 |
Embolism | 0 (0.0) | 9 (0.1) | 0.37 |
Pulmonary embolism | 4 (0.1) | 15 (0.1) | 0.84 |
Deep vein thrombosis | 16 (0.5) | 39 (0.3) | 0.02 |
Atherosclerosis | 6 (0.2) | 15 (0.1) | 0.24 |
Coagulopathy | 5 (0.2) | 26 (0.2) | 1.0 |
Hypertension | 75 (2.5) | 220 (1.4) | 0.0001 |
Diabetes | 42 (1.4) | 101 (0.7) | 0.0001 |
Diagnosis of alcohol misuse | 53 (1.7) | 123 (0.8) | 0.0001 |
Chronic obstructive lung disease | 21 (0.7) | 42 (0.3) | 0.0007 |
Malignancy | 37 (1.2) | 178 (1.2) | 0.90 |
Chronic renal disease | 16 (0.5) | 52 (0.3) | 0.17 |
Abnormal liver function | 14 (0.5) | 58 (0.4) | 0.64 |
Medication, n (%) | |||
Beta-blockers | 82 (2.7) | 247 (1.6) | 0.0001 |
Calcium channel blockers | 38 (1.3) | 132 (0.9) | 0.06 |
RAS inhibitors | 38 (1.3) | 164 (1.1) | 0.47 |
Vasodilators | 0(0.0) | 0 (0.0) | 1.0 |
Antiadrenergic drugs | 8 (0.3) | 8 (0.1) | 0.001 |
Thiazides | 84 (2.8) | 270 (1.8) | 0.0004 |
Loop diuretics | 57 (1.9) | 117 (0.8) | 0.0001 |
Spironolactone | 11 (0.4) | 14 (0.1) | 0.0007 |
Diuretics, combination | 12 (0.4) | 49 (0.3) | 0.65 |
Digoxin | 6 (0.2) | 27 (0.2) | 1.0 |
Statins | 18 (0.6) | 74 (0.5) | 0.54 |
Antidiabetics | 55 (1.8) | 107 (0.7) | 0.0001 |
Aspirin | 33 (1.1) | 108 (0.7) | 0.04 |
ADP inhibitors | 0 (0.0) | 0 (0.0) | 1.0 |
Anticoagulants | 5 (0.2) | 23 (0.2) | 1.0 |